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ACTH Antagonists
Adrian John Clark1*, Rachel Forfar2, Mashal Hussain1, Jeff Jerman2, Ed McIver2,  
Debra Taylor2 and Li Chan1
1 Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, UK, 2 Centre for 
Therapeutics Discovery, MRC Technology, Stevenage, UK
Adrenocorticotropin (ACTH) acts via a highly selective receptor that is a member of 
the melanocortin receptor subfamily of type 1 G protein-coupled receptors. The ACTH 
receptor, also known as the melanocortin 2 receptor (MC2R), is unusual in that it is 
absolutely dependent on a small accessory protein, melanocortin receptor accessory 
protein (MRAP) for cell surface expression and function. ACTH is the only known 
naturally occurring agonist for this receptor. This lack of redundancy and high degree 
of ligand specificity suggests that antagonism of this receptor could provide a useful 
therapeutic aid and a potential investigational tool. Clinical situations in which this could 
be useful include (1) Cushing’s disease and ectopic ACTH syndrome – especially while 
preparing for definitive treatment of a causative tumor, or in refractory cases, or (2) con-
genital adrenal hyperplasia – as an adjunct to glucocorticoid replacement. A case for 
antagonism in other clinical situations in which there is ACTH excess can also be made. 
In this article, we will explore the scientific and clinical case for an ACTH antagonist, 
and will review the evidence for existing and recently described peptides and modified 
peptides in this role.
Keywords: adrenocorticotropin hormone, receptor antagonism, Cushing’s syndrome, congenital adrenal 
hyperplasia, high throughput screening, G protein-coupled receptor, receptor modelling, peptide hormone 
antagonists
iNTRODUCTiON
The impact of receptor antagonism on modern medicine cannot be understated. Classical 
examples include the β-blockers in the treatment of hypertension and cardiovascular disease (1) 
and histamine H2 antagonism in the treatment of gastric hyperacidity (2). Even in the field of 
endocrinology, receptor antagonism of steroid hormones [e.g., tamoxifen (3), eplerenone (4), and 
flutamide (5)] and some peptide hormones [e.g., pegvisomant (6) and conivaptan (7)] has had 
major life-changing impact. The pituitary–adrenal axis is one endocrine axis that when disrupted 
can be associated with a wide range of pathologies, and yet, despite the fact that it comprises several 
unique and thus highly targetable components, receptor antagonism has received little attention 
as a therapeutic approach.
In this article, we will examine the possible benefits of development of an effective antagonist 
to a key component of this axis, the peptide hormone adrenocorticotropin (ACTH). The disorders 
in which clinical benefit might be attained will be considered. We will then consider the nature of 
the target – ACTH and the ACTH receptor complex, and certain unique features before discussing 
the history of ACTH antagonist research, ending with a description of the current state-of-the art. 
Initially, a brief description of the pituitary–adrenal axis and its key components is necessary.
TABLe 1 | A summary of the main features of each of the melanocortin receptors in the human.
Major sites of 
expression
Ligand preference Function effect of deletion Comments
MC1R Melanocytes α-MSH > ACTH > γ-MSH Pigmentation of hair and skin Red hair, pale skin Agouti antagonizes
MC2R Adrenal cortex ACTH Steroidogenesis adrenal growth Adrenal failure Absolute dependency on MRAP
MC3R Brain, spinal cord γ-MSH > α-MSH = ACTH Complex, inhibits POMC neurones Obesity
MC4R Brain, spinal cord α-MSH > ACTH > γ-MSH Appetite regulation Obesity Enhanced action with MRAP2 
AGRP is natural antagonist
MC5R Multiple tissues α-MSH > ACTH > γ-MSH Exocrine gland function Defective water 
repulsion
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THe PiTUiTARY–ADReNAL AXiS
The corticotroph cells of the anterior pituitary gland are 
responsible for synthesis and secretion of the 39 residue peptide, 
ACTH (8). ACTH is derived from a larger precursor protein, 
pro-opiomelanocortin (POMC), by the action of a specific 
pro-hormone convertase enzyme (PC1 or PCSK1) (9). In other 
tissues  –  for example, the hypothalamus  –  this precursor is 
processed differently to produce α-MSH instead of ACTH (10). 
ACTH is synthesized and secreted by the pituitary in response to 
tonic control from the hypothalamus – principally in the form 
of two peptide hormones  –  corticotrophin-releasing hormone 
(CRH) and vasopressin (AVP), which in turn are regulated by 
multiple higher factors including stress (11).
Adrenocorticotropin has a short half-life in the circulation 
(12) and acts on a highly specific G protein-coupled receptor 
expressed almost uniquely in the adrenal cortex (13). This recep-
tor, the MC2R is one of five members of the melanocortin receptor 
family – see Table 1. ACTH can activate all five of these receptors, 
although at physiological circulating levels, the sensitivity of the 
other receptors is such that they are not activated. Importantly, the 
naturally occurring agonists for these other receptors – α-MSH, 
γ-MSH, and possibly β-MSH  –  have no affinity for the MC2R 
(14, 15). Thus the MC2R is a highly sensitive and highly specific 
receptor for ACTH with a major, essential function of stimulating 
the fasciculata cells of the adrenal cortex to synthesize and secrete 
glucocorticoid. In addition, ACTH can stimulate zona glomeru-
losa cells to secrete mineralocorticoid and zona reticularis cells to 
secrete adrenal androgens.
Glucocorticoid (cortisol in man and most other species, 
corticosterone in rodents), secreted by the adrenal gland exert 
a plethora of physiological actions on virtually every cell in the 
organism. These actions are the result of interaction with the 
widely expressed glucocorticoid receptor  –  a nuclear hormone 
receptor. Glucocorticoid may also activate a second related 
receptor – the mineralocorticoid receptor – which is less widely 
expressed. However, the action of the 11 β-hydroxysteroid 
dehydrogenase type 2 enzyme inactivates glucocorticoid in 
mineralocorticoid receptor expressing tissues under normal 
circumstances leaving these receptors responsive to aldosterone 
(16). From an endocrine perspective, a key role of glucocorticoid 
is to feedback negatively on the pituitary and hypothalamus to 
inhibit ACTH secretion (17).
From this brief description, it can be seen that in theory, the 
MC2R should provide a perfect substrate for receptor targeting. 
This is a receptor with, effectively, a single function, expressed 
in a highly tissue-restricted way and activated by a single, highly 
specific agonist. The question is – if it were possible to design the 
perfect antagonist – what clinical role might it play?
DiSORDeRS OF THe PiTUiTARY–
ADReNAL AXiS
Disorders of this axis are, fortunately, uncommon and can be 
subdivided into disorders of hormone deficiency and excess. 
Glucocorticoid deficiency seems unlikely to benefit from MC2R 
antagonism, but in certain specific circumstances, there could be 
a valuable role for this therapeutic option as discussed later.
Glucocorticoid excess
Glucocorticoid excess may result from primary adrenal 
disease  –  typically an adrenal adenoma or carcinoma  –  and is 
independent of ACTH. Indeed ACTH is normally suppressed by 
the actions of the negative feedback loop. More often, cortisol 
excess or Cushing’s syndrome is the result of a pituitary adenoma 
secreting excess ACTH – known as Cushing’s Disease – or less 
commonly a non-pituitary tumor that “ectopically” secretes 
ACTH. This group of disorders might theoretically provide a 
suitable target for an MC2R antagonist.
Cushing’s Disease
Corticotroph adenomas are small, usually slow growing, benign 
tumors that normally come to clinical attention as a result of the 
effects of glucocorticoid excess, rather than because of the physi-
cal effects of an expanding tumor. Typically, Cushing’s syndrome 
may take many years to develop. Consequently the diagnosis of 
the disorder and exclusion of other causes of Cushing’s syndrome 
is a significant challenge. Once a diagnosis is conclusively made, 
the optimal treatment is surgical removal of the tumor  –  ide-
ally preserving the remaining pituitary function. Surgery for 
Cushing’s disease requires extensive experience and skill and is 
normally undertaken in specialist centers (18).
In some patients, the metabolic consequences of their 
untreated glucocorticoid excess are so significant that there 
would be risks in immediately proceeding to complex or 
prolonged surgery. The glucocorticoid synthesis blockers 
metyrapone and/or ketoconazole are frequently used in this 
situation to reduce steroid production (see Figure 1), and most 
patients tolerate and respond to this treatment reasonably well 
(19–21). However, an MC2R antagonist could be equally effec-
tive in this situation.
Cholesterol
Pregnenolone
Progesterone                          17α-Progesterone
11-Deoxycorcosterone                 11-Deoxycorsol
Aldosterone Corsol
17 αOH-Pregnenolone
P450 Side Chain Cleavage
P450 c11B1
11β-hydroxylase
DHEA A4
Testosterone
P450c17
(17 α-hydroxylase)
P450c11B2
(Aldo synthase)
P450c21
21-Hydroxylase
3β-Hydroxysteroid
Dehydrogenase
3β-Hydroxysteroid
Dehydrogenase
FiGURe 1 | Major steroid synthetic pathways in the human showing the three main end products – cortisol, testosterone and aldosterone, the key 
intermediates, and the main enzymes. 21-Hydroxylase deficiency (enzyme highlighted in yellow) is the major cause of congenital adrenal hyperplasia. It can be 
seen that deficiency or inhibition will result in cortisol and aldosterone deficiency and androgen excess. Inhibition of 17 α-hydroxylase (highlighted in red) by 
abiraterone in contrast will lead to cortisol and testosterone deficiency and overproduction of aldosterone. Metyrapone inhibits 11 β-hydroxylase (highlighted in 
green) and this may lead to an overproduction of adrenal androgens. The p450 inhibitor, ketoconazole will impair the action of all these enzymes and other P450 
enzymes (shown in blue) and thus will not result in overproduction of steroid.
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Following surgery, the glucocorticoid excess will come 
under rapid control in a minority of patients. More frequently, 
there will be a reduction in steroid over-secretion that may 
tail off over several weeks. In other cases, it may be necessary 
to re-explore the pituitary surgically, and this may result in 
pituitary clearance with a loss of other pituitary hormones 
(18). Control of glucocorticoid excess during this interim 
period will often necessitate the use of metyrapone and/or 
ketoconazole.
If further surgical measures are unsuccessful, endocrinologists 
may turn to the somatostatin receptor 5 agonist, pasireotide, 
which directly targets the corticotroph adenoma and provides 
partial or complete control of Cushing’s in a proportion of cases 
(22). Other second-line options in this situation include pituitary 
radiotherapy or adrenalectomy. The former may take several years 
to normalize the glucocorticoid excess, necessitating metyrapone 
and/or ketoconazole during this time. An MC2R antagonist could 
be a possible alternative.
While glucocorticoid synthesis inhibitors are usually effective 
and reasonably well tolerated in these situations, there are some 
potential disadvantages to their prolonged use. Metyrapone 
blocks the 11β-hydroxylase enzyme, required for the last step 
of cortisol synthesis from 11-deoxycortisol. Consequently, as 
shown in Figure  1, steroid precursors are channeled through 
the androgen pathways resulting in increased secretion of adrenal 
androgens. In women, this may induce hirsutism and in pre-
pubertal children both virilization and early puberty (23,  24). 
Ketoconazole, a cytochrome P450 inhibitor, inhibits several 
steps of steroidogenesis and does not usually cause androgen 
excess. However, complications include potential rare but serious 
hepatotoxicity and multiple drug interactions. Consequently, 
although these treatments are effective and inexpensive, there 
could be a place for a highly specific MC2R antagonist in the 
management of Cushing’s disease.
Ectopic ACTH Syndrome
The mechanisms of ectopic ACTH syndrome are essentially the 
same as those of Cushing’s disease except that the underlying 
tumor is outside the pituitary gland. These rare tumors are often 
small carcinoid tumors that may occur anywhere in the lungs 
and gastrointestinal tract. Improvements in imaging over the last 
10–20 years together with intravenous sampling for ACTH have 
made identification of the primary source far simpler. Once iden-
tified, and if surgical removal of the underlying tumor is possible, 
then this can be curative. As with Cushing’s disease, it may be 
helpful to use a cortisol synthesis blocking drug while waiting for 
definitive treatment (18) and in cases where definitive treatment 
is not possible. Hence, for the same reasons described above, an 
MC2R antagonist may have a place in the clinical management 
of such conditions.
Small cell lung cancer makes up about 20% of all lung cancer 
is a highly malignant neuroendocrine tumor of poor prognosis. 
This tumor is frequently associated with ectopic ACTH secretion, 
and the development of Cushing’s syndrome in this disease may 
obviously worsen prognosis. Thus there may also be value in 
using an ACTH antagonist in this clinical situation.
4Clark et al. ACTH Antagonists
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Glucocorticoid Deficiency
The second group of disorders in which there may be an place 
for antagonizing ACTH action are those in which the physiologi-
cal negative feedback of cortisol is reduced or lost, leading to a 
compensatory increase in ACTH secretion. In this situation, it is 
the stimulation of non-glucocorticoid adrenal steroidogenesis by 
ACTH, which requires control.
Congenital Adrenal Hyperplasia
The most prominent example of such a situation is that of congenital 
adrenal hyperplasia, caused in the majority of cases by mutations 
in both alleles of the CYP21 gene encoding the 21-hydroxylase 
enzyme necessary for the penultimate step of cortisol synthesis 
(Figure 1) (25, 26). This is one of the commonest human autoso-
mal recessive disorders occurring in about 1 in 15,000 live births. 
Reduced glucocorticoid feedback results in ACTH stimulation of 
adrenal androgen production. As a consequence, affected female 
children are likely to be virilized or have ambiguous genitalia 
at presentation. Life-long treatment with glucocorticoids will 
restore any cortisol deficiency and suppress ACTH secretion and 
subsequent androgen production (27). However, achieving the 
optimal dose and timings of hydrocortisone replacement to avoid 
the adverse effects of excessive glucocorticoid on growth and 
metabolism while maintaining adequate androgen suppression is 
challenging, resulting in poor health outcomes (28). Availability 
of an easily administered ACTH antagonist would be likely to 
facilitate treatment, allowing a “block and replace” approach in 
which the physician could focus on treatment of glucocorticoid 
replacement alone rather than androgen suppression.
Prostate Cancer Treatment
The use of the drug Abiratarone in the treatment of prostate cancer 
induces a form of acquired adrenal hyperplasia. Abiratarone is a 
potent inhibitor of the 17 α-hydroxylase and 17,20 lyase enzymes 
in the adrenal and is used to very effectively reduce the production 
of adrenal androgens in castration-resistant prostate cancer, with 
valuable benefits to prostate cancer treatment (29). Examination 
of adrenal steroid synthetic pathways (Figure  1) demonstrates 
that this inhibition is likely to channel steroid synthesis toward 
deoxycorticosterone synthesis and aldosterone production, lead-
ing to mineralocorticoid excess and glucocorticoid deficiency. 
The latter requires glucocorticoid replacement, but the fluid over-
load, hypertension, and hypokalemia resulting from aldosterone 
excess require treatment with a mineralocorticoid antagonist 
such as eplerenone (30). Use of an ACTH antagonist together 
with a replacement dose of hydrocortisone may be a preferred 
approach in this situation.
investigation of endocrine Disease
A further potential use of an ACTH antagonist is in the investiga-
tion of adrenal disorders. One of the key questions in the inves-
tigation of Cushing’s syndrome is whether the cortisol excess is 
ACTH dependent. A number of tests have been used to determine 
this including the dexamethasone suppression test and the CRH 
stimulation test, combined with measurements of plasma ACTH 
and imaging studies. Hypoglycemic stress tests and metyrapone 
tests may also be required in complex cases (31). It is conceivable 
that the use of a single dose ACTH antagonist test could provide 
a simple and clear solution to this question, although it is more 
likely that its use in combination with other investigations would 
be required in most cases.
THe TARGeT
As discussed in the Section “Introduction,” the receptor for 
ACTH presents a remarkably attractive target for pharmaco-
logical manipulation. It is highly specific for a single peptide 
agonist – ACTH [1–39], and has no affinity or response to any 
other naturally occurring agonist. It is expressed in functional 
quantities only in the adrenal cortex, and thus the possibility of 
unwanted off-target effects of an antagonist is unlikely.
The key component of the ACTH receptor complex is the 
seven transmembrane domain MC2R  –  perhaps surprisingly, 
the smallest of all the G protein-coupled receptor (GPCR) family 
at only 289 residues in length (32). The MC2R cannot function 
alone as an ACTH receptor, which led to many difficulties in its 
characterization after initial cloning (33). The discovery that defi-
ciency of a small, single transmembrane domain protein caused 
a clinical syndrome essentially identical to that caused by MC2R 
deficiency led to the identification of the melanocortin 2 receptor 
accessory protein (MRAP) as the MC2R co-receptor (34, 35).
Melanocortin receptor accessory protein is a highly unusual 
protein in that it naturally exists as an antiparallel homodimer 
and seems to be necessary for trafficking and cell surface expres-
sion of the MC2R, as well as binding of ACTH and hence signal 
transduction (36, 37). In common, with many other GPCRs, 
MC2R has the potential to homodimerise and the evidence sug-
gests that it exists as a homodimer with two MRAP molecules, 
in an antiparallel homodimer formation, associated with each 
MC2R component (38) (Figure 2).
The nature of the ligand, ACTH is important in understand-
ing receptor function (Figure  3A). The strongly conserved 
N-terminal 24 residues of ACTH are almost as efficient as the 
39 residue naturally occurring peptide in activating this receptor. 
Further truncation of ACTH from the C-terminus is associated 
with gradual loss of activity until removal of the four basic resi-
dues (Lys–Lys–Arg–Arg) in positions 15–18, which inactivates 
this peptide at the ACTH receptor (39, 40). The first 13 residues 
are however active at all the other melanocortin receptors and 
thus it seems that this “tetrabasic” region acts as a “key” to unlock 
the MC2R–MRAP complex.
The evidence suggests that once the receptor is “unlocked,” 
the N-terminal region is an effective agonist for the receptor. 
As with all the melanocortin receptors, the His–Phe–Arg–Trp 
sequence (or HFRW sequence using the single letter amino acid 
code) at positions 6–9 and to some extent those residues flanking 
this induce the conformational changes required to activate the 
receptor. This HFRW sequence is fundamental to activation of all 
the melanocortin receptors and can be considered the “message” 
region of the peptide (40, 43, 44). Interestingly, a naturally occur-
ring human mutation of Arg 8 in the HFRW sequence results 
in biologically inactive ACTH (45). The most N-terminal region 
(Ser–Tyr–Ser) has been reported to potentiate the action of the 
HFRW sequence (46).
NC
N
C
C
C
N
N
C
N
C
MRAP MC2R
Dimeric MC2R-MRAP 
Complex
FiGURe 2 | Diagrammatic representation of the components of the 
ACTH receptor complex. MRAP (pink) exists as an antiparallel homodimer 
with one short N-terminus and one longer C-terminus on either side of the 
plasma membrane. The cylindrical components represent the α-helical 
transmembrane domains. MC2R (blue) contains seven transmembrane 
domains (blue cylinders) with an N-terminal extracellular domain and a 
C-terminal intracellular domain. Evidence suggests that one MRAP 
homodimer associates with one MC2R molecule and that MC2R probably 
exist as homodimers as shown in the lower panel, or possibly as higher 
order multimers.
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Great strides have been made in recent years in understanding 
the three dimensional nature of GPCRs, based around a growing 
number of receptor crystal structures. No melanocortin receptor 
crystal structure has yet been reported, but increasingly sophis-
ticated modeling exercises combined with receptor mutagenesis 
and substitution studies are providing information on how ligands 
interact with their receptor.
Pogozheva et  al. studied the MC4R-binding site for NDP-
MSH (a highly potent analog of α-MSH) and two small molecule 
agonists using a combination of alanine scanning mutagenesis of 
the receptor followed by functional analysis and in silico mod-
eling. They concluded that the HFRW sequence of NDP-MSH 
was required to form a β-hairpin-like structure so that the 
phenyl ring of Phe 7 interacts with the indole ring of Trp 9 
(Figure 3B). This allows interaction between His 6 of NDP-MSH 
and Glu 100 in transmembrane domain 2 (TM2) of MC4R, and 
Arg 8 of NDP-MSH and Asp 115 and 119 inTM3 of MC4R. The 
interacting aromatic residues of this sequence, Phe 7 and Trp 9 
interact with the aromatic Phe at positions 261 and His 264 of 
MC4R in TM6 (41).
A relatively similar picture of NDP-MSH binding to the 
MC5R was constructed by Yang and colleagues using site-
directed mutagenesis and structural modeling. They also sug-
gested that Asp 115 and 119 in TMD 3 interact with Arg 8 of 
the HFRW sequence and that Phe 195 (in TMD 5) and Phe 254 
(TMD 6) interact with Phe 7 and Trp 9 of HFRW. All of these 
residues are conserved in the MC2R (and other melanocortin 
receptors), and it seems highly likely that these interactions 
are critical in determining the HFRW binding and activation 
of this receptor (42). Indeed, naturally occurring homozygous 
mutations of Asp 103 and 107 in MC2R, the equivalent con-
served Asp residues in this receptor, lead to ACTH resistance/
Familial Glucocorticoid Deficiency (47). This arrangement is 
shown in Figure 3C.
Using a receptor chimera approach in which regions of the 
MC4R were substituted into the MC2R, Fridmanis et  al. sug-
gested that one of the MRAP molecules binds to MC2R in the 
region of transmembrane domains 4 and 5 to create a binding 
pocket for the tetrabasic “address” sequence in ACTH. Following 
this interaction, a conformational shift in the receptor transmem-
brane domains takes place, which permits the formation of the 
HFRW-binding pocket (14). Although this remains speculative, 
it is an attractive hypothesis. It is notable that Malik et al. have 
shown that it is the N-terminal region of the MRAP molecule 
that is required on the extracellular surface of the cell for ACTH 
binding (48). Clearly complete understanding of this complex 
area will ultimately require determination of a crystal structure 
of the MC2R–MRAP–ACTH complex.
APPROACHeS TO ANTAGONiZiNG ACTH
Given the extensive knowledge of the interaction of ACTH with 
its receptor gained over about 50  years one might anticipate 
that it would be a relatively straightforward matter to design an 
ACTH-like peptide with antagonist properties. The first attempts 
to do this resulted in peptides that retained the tetrabasic address 
region, but lacked the HFRW message sequence. This led to the 
development of ACTH [11–24] (49, 50) as a potential receptor 
antagonist. Li et al. isolated a naturally occurring peptide, ACTH 
[8–39], from human pituitary, which they showed to have ACTH 
antagonistic effects in vitro, and they called this corticotrophin-
inhibiting peptide (CIP) (51). However, the data with each of 
these potential antagonists has been confusing with discrepant 
results for steroidogenesis and cAMP generation in some cases. 
For example, Szalay demonstrated that ACTH [11–24] stimulated 
steroidogenesis in dispersed zona glomerulosa and zona fascicu-
lata cells (52), and Goverde and Smals (53) demonstrated some 
steroidogenesis with this peptide.
More recently, Kovalitskaia et al. investigated the binding of a 
wide range of ACTH fragments derived from an ACTH [11–24] 
parent peptide. They reported that the ACTH [15–18] tetrabasic 
fragment alone was an effective competitor for ACTH [11–24] in 
ligand-binding assays, and that it also failed to stimulate cAMP 
generation in adrenocortical membranes (54). Its use in competi-
tion with ACTH in cAMP generation or steroidogenesis has not 
been reported.
The consensus from most researchers seems to be that ACTH 
[11–24] is not an effective ACTH antagonist. This may be because 
the interaction between the tetrabasic region of ACTH converts 
the MC2R into a “primed receptor with an unoccupied HFRW-
binding site, which may then be activated by the natural agonist.” 
Hoffman therefore used a different approach and developed 
an analog in which the Trp residue at position 9 of the HFRW 
message sequence was substituted with Phe or N-methyl Trp, 
S Y S M E G K P V G P V K V Y PYRFH K K R R
1 10 15 205 24
‘Message’ 
sequence
‘Address’ 
sequence
α-MSH sequence
………..
39
His 6
Phe 7
Arg 8
Trp 9 Phe HisArg
Trp
TM2TM3
TM6TM5
F235
H238
D103 E80D107
TM7
TM1
TM4
F182
A
B C
FiGURe 3 | (A) Amino acid sequence of ACTH [1-24] using the single letter amino acid code. Note – the naturally occurring peptide is 39 residues in length. The 
key functional domains are the “message” sequence (yellow), which is required for activation of all the melanocortin receptors, and the “address” sequence (red), 
which enables only ACTH to activate the MC2R. α-MSH is equivalent to the first 13 residues of ACTH. (B) The “message” sequence folds into a β-hairpin loop in 
which the aromatic amino acids Phe 7 and Trp 9 interact with each other via their phenyl and indole rings, respectively, as shown. (C) If the MC2R is viewed from 
above, each of the transmembrane domains is seen as a blue circle (labeled TM1, TM2, etc). By extrapolation from modeling data from the MC4R (41) and from the 
MC5R (42), it seems likely that His 6 of ACTH interacts with E80 in TM2 of the MC2R, and Arg 8 interacts with D103 and 107 (of MC2R). Phe 7 and Trp 9 interact 
with multiple residues including F182, F235, and H238 of MC2R.
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and showed inhibition of ACTH stimulated cAMP generation on 
bovine adrenal membranes (55).
Liang et  al. has described a number of peptide analogs of 
ACTH based on alanine and histidine substitutions around the 
HFRW region and in the spacing between this and the tetrabasic 
region (56). In this work, they described the marked reduction in 
MC2R activation observed with some of these peptides and, in a 
US patent filed the preceeding year, they reported potent ACTH 
antagonism with an ACTH [15–24] decapeptide (57).
In all of the above studies, the actions on adrenal tissues, slices, 
cells, or membranes have been studied, but little or no data on 
the selectivity of these peptide antagonists for the MC2R, or 
even melanocortin receptors in general have been obtained. It is 
usually highly desirable that any receptor active drug used thera-
peutically is selective for its target receptor and lacks off-target 
effects. The functions of the other melanocortin receptors and 
the effects of antagonizing or deleting them are summarized in 
Table 1, and it can be seen that a non-selective agent could induce 
a number of unwanted effects.
Bouw and colleagues reported an approach in which ACTH 
peptides that retain the intact tetrabasic region were substituted 
at various positions in the HFRW sequence and in some cases 
were cyclized in order to enhance stability. HEK293 cells stably 
expressing human MC2R and MRAP were used, and cAMP 
production was measured with a luminescence assay. Several 
peptides exhibited significant antagonist actions among which 
GPS1573 – a variant of ACTH [7–18] with an N-terminal nor 
leucine – proline sequence and d-Phe and dd-Trp (in place of the 
l-Phe and l-Trp) in the HFRW sequence, and a cyclized variant 
of this – GPS1574 were most potent (IC50s of 66 ± 23 nM and 
260 ± 1 nM, respectively). These peptides retain some antagonist 
effect on the MC3R, MC4R and MC5R at approximately an order 
of magnitude less than that on the MC2R (58).
In work published in this issue, Nensey et al. report the actions 
of these same analogs on rat adrenal cells and show inhibitory 
effects in which the dose responses to ACTH [1–39] were shifted 
to the right by one log order or more. They also conducted in vivo 
experiments in young rats but were unable to show inhibition of 
the ACTH response even at 400-fold molar excess of antagonist in 
the case of GPS1573. GPS1574 was partially inhibitory at 30 min 
after ACTH injection (59).
In a recent study, presented in abstract form, researchers from 
Ipsen Bioscience Inc. reported the development of an ACTH-
related peptide, IRC-274. This peptide was shown to inhibit ACTH 
binding to the human MC2R and MRAP expressed in HEK 293 
cells with an IC50 of 3 nM (60). cAMP generation in response to 
ACTH in this same model is inhibited with an IC50 of 38 nM. 
Using an in vivo hypophysectomized rat model in which ACTH is 
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infused by osmotic minipump, significant inhibition of corticos-
terone production was observed. Using a second model in which 
mouse AtT20 pituitary corticotroph tumor cells were implanted 
into athymic nude mice, inhibition of corticosterone was again 
observed until the implanted tumors outgrew the inhibitory 
action of IRC-274. Interestingly, this antagonist exhibits a high 
degree of selectivity for the MC2R and has no significant actions 
on other melanocortin receptors. The sequence and structure of 
this peptide have not been revealed.
ALTeRNATive APPROACHeS
Small Molecules
From the above, it seems that after a rather long and chequered 
history some progress is now being made in developing a peptide 
ACTH antagonist that might ultimately be developed for use 
in vivo. The problems associated with peptide-based medication 
are well-known and include a short half-life in the circulation, 
the need to administer them by injection and the risk of induc-
ing immunogenicity. In certain circumstances, the benefits of a 
peptide outweigh these potential disadvantages, and advances 
are being made in deriving preparations of peptides that may be 
taken orally or intranasally. However in many cases, there will 
be a need for a reliable long-term therapy as discussed earlier. 
Under these circumstances, it would be desirable to have an orally 
active agent, which would most likely be a small (non-peptide) 
molecule. Substantial efforts have been made to develop small 
molecules as agonists of the MC4 receptor with some limited 
success (61). With this objective in mind, we have undertaken a 
high throughput screen of about 200,000 small molecules using 
a cell-line expressing the human MC2R and MRAP, and this 
may provide a promising approach if a molecule with sufficient 
potency and selectivity can be identified.
Antibody-Based Approaches
Humanized monoclonal antibodies directed against key signaling 
molecules have proven to provide effective therapeutic solutions 
in inflammatory diseases and cancer. This approach has been 
used to target ACTH and the pituitary–adrenal axis by a number 
of investigators and one pharmaceutical company aims to begin 
human studies in the near future (62). While such antibodies may 
not necessarily provide a long-term therapeutic solution, they 
seem likely to have potential in shorter-term therapeutic situa-
tions, such as around the time of pituitary surgery for Cushing’s 
disease.
Corticostatins
Solomon and colleagues identified a novel lung and neutrophil 
peptide belonging to the defensin class of highly cationic antimi-
crobial peptides. They showed this peptide exhibited a number 
of functions including inhibition of ACTH binding and corti-
costerone secretion and named this corticostatin (63). It is also 
known as defensin α-4. These functions appear to be relatively 
non-specific, and little work has been published on this in recent 
years. We are not aware that this action of corticostatin has been 
explored for therapeutic purposes.
SUMMARY
We have reviewed the case for the development of an ACTH 
antagonist for therapeutic purposes. The conditions in which 
there is a potential clinical indication are relatively uncom-
mon, and alternative therapies are well described in each case. 
However as a refinement to existing therapies or for the treat-
ment of particularly difficult or complex cases, there would be a 
real clinical benefit. We have not considered a number of more 
common conditions, such as depressive illness or septic shock in 
which there might ultimately be a role for an ACTH antagonist, 
although these have been considered elsewhere (64).
The evidence suggests that progress is being made on more 
than one front in developing an antagonist. This has been delayed 
for many years by the absence of “clean” systems in which to test 
candidate peptides and compounds, owing to the problems in 
expressing the MC2R. This should no longer be a problem as 
a result of the identification of MRAP that enables cell surface 
expression of the MC2R. As a result there does seem to be a grow-
ing interest in this area and the next decade may witness exciting 
developments.
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